Pulmatrix Q2 loss narrows on clinical development hold - PULM News | RalliesPulmatrix Q2 loss narrows on clinical development hold
P
PULM• Outlook
- Company expects proposed merger with Eos SENOLYTIX to close in Q3 2026
- All clinical development on hold while company seeks to license or monetize clinical assets
- Pulmatrix anticipates cash position is sufficient to fund operations through expected merger closing
Overview
- U.S. biopharma firm's Q2 net loss narrowed as general and administrative expenses declined
- All clinical development on hold as company seeks to license or monetize clinical assets
- Company focused on completing proposed merger with Eos SENOLYTIX in Q3 2026
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Loss Per Share | | $0.29 | |
Result Drivers
- MERGER FOCUS - Co said it prioritized advancing steps toward completing proposed merger with Eos SENOLYTIX
- CLINICAL DEVELOPMENT ON HOLD - All clinical development is currently on hold while co works to license or monetize clinical assets
- - General and administrative expenses fell due to lower software, legal, patent, and merger-related costs
LOWER OPERATING COSTS
